Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.
about
Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic ImplicationsOverexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma.Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer.Recent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies.Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery.Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer.Polycomb Repressive Complex 2 regulates lineage fidelity during embryonic stem cell differentiationOverexpression and lack of copy number variation in the BMI-1 gene in human gliomaBMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistanceEwing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group.Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer.Polycomb group proteins are key regulators of keratinocyte functionEpigenetic factors in cancer development: polycomb group proteins.Gene silencing by the Polycomb group proteins and associations with cancer.Epigenetics of melanoma: implications for immune-based therapies.Tissue prognostic biomarkers in primary cutaneous melanoma.Genetic alterations and personalized medicine in melanoma: progress and future prospects.Polycomb group proteins--epigenetic repressors with emerging roles in melanocytes and melanoma.SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression.Differential BMI1, TWIST1, SNAI2 mRNA expression pattern correlation with malignancy type in a spectrum of common cutaneous malignancies: basal cell carcinoma, squamous cell carcinoma, and melanoma.Loss of β-arrestin-2 and Activation of CXCR2 Correlate with Lymph Node Metastasis in Non-small Cell Lung Cancer.Decreased expression of RASSF6 is a novel independent prognostic marker of a worse outcome in gastric cancer patients after curative surgery.
P2860
Q26801380-3FEAD671-5374-4508-BF3F-AFA3F12BA494Q30999677-C33B9162-04D4-4D50-8F76-E5C7F22392C2Q33630849-5A23B817-3F78-4E9E-BD14-DEA852F554C0Q34044908-7D4151E0-461A-4EFF-94F7-18EBB38AAF3BQ34250198-DA0A10C4-8711-4711-97E4-72F320812053Q34760721-5FFEA547-4F2B-407B-BC7D-E8D281C1E850Q35354687-ED7BD277-E280-4736-A680-54C5E90FBACEQ36336437-C9DDB219-B095-4FED-A722-2A709F283425Q36432043-3F033203-CF6C-4689-BBFC-3DA6DA0FC62BQ37012862-0E6A3505-E4CD-4AF2-9F7D-D923C9505535Q37629613-72C9FD6C-4A76-40E6-9088-ECFEF7E72C3BQ37810463-2A40DF66-8793-4AAA-B266-38C2FB5C0250Q37822735-9711A5B5-0A8A-4173-91CD-277E4D5C0AE5Q37835825-76AD05D1-DA4E-4E8B-9104-C9687375AB32Q38148588-796B04C0-3554-4EBC-B047-BEF7725F25B7Q38184377-406A3BA9-4DB1-4C96-B6BD-D2095CDF3799Q38186704-9E2CE788-AECE-4970-B276-05277D7ADB8CQ38283093-5E7EF877-6DEC-4C78-8861-7DF324AC83B5Q38953852-9771A51A-76F1-4CC7-8B8D-FF473FCE8830Q40549663-BC6B9250-9630-4576-AACD-14BF69AC0FBEQ41721776-E8206E49-DD1B-4390-8C44-20F2D286654EQ44130414-B4090DB0-57B6-45C5-9144-823BFE340024
P2860
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.
@en
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.
@nl
type
label
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.
@en
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.
@nl
prefLabel
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.
@en
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.
@nl
P2093
P2860
P1433
P1476
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.
@en
P2093
Arie P Otte
Hanne E Puntervoll
Ingeborg M Bachmann
P2860
P2888
P304
P356
10.1038/MODPATHOL.2008.17
P577
2008-02-08T00:00:00Z